Calcifediol Patent Expiration
Calcifediol is Used for treating secondary hyperparathyroidism in patients with chronic kidney disease. It was first introduced by Organon Usa Inc
Calcifediol Patents
Given below is the list of patents protecting Calcifediol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rayaldee | US10300078 | Stabilized modified release vitamin D formulation and method of administering same | Mar 14, 2034 | Eirgen |
| Rayaldee | US10357502 | Stabilized modified release vitamin D formulation and method of administering same | Mar 14, 2034 | Eirgen |
| Rayaldee | US11253528 | Stabilized modified release Vitamin D formulation and method of administering same | Mar 14, 2034 | Eirgen |
| Rayaldee | US9861644 | Stabilized modified release vitamin D formulation and method of administering same | Mar 14, 2034 | Eirgen |
| Rayaldee | US11801253 | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease | Sep 07, 2030 | Eirgen |
| Rayaldee | US8426391 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | Aug 27, 2028 | Eirgen |
| Rayaldee | US8361488 | Methods and compositions for controlled release oral dosage of a vitamin D compound | Jul 19, 2028 | Eirgen |
| Rayaldee | US11154509 | Methods for controlled release oral dosage of a vitamin D compound | Apr 25, 2028 | Eirgen |
| Rayaldee | US8207149 | Method for treating secondary hyperparathyroidism in CKD | Apr 25, 2028 | Eirgen |
| Rayaldee | US8778373 | Methods for controlled release oral dosage of a vitamin D compound | Apr 25, 2028 | Eirgen |
| Rayaldee | US9408858 | Method for treating secondary hyperparathyroidism in CKD | Apr 25, 2028 | Eirgen |
| Rayaldee | US9498486 | Method for controlled release oral dosage of a vitamin D compound | Apr 25, 2028 | Eirgen |
| Rayaldee | US9925147 | Method for treating secondary hyperparathyroidism in CKD | Apr 25, 2028 | Eirgen |
| Rayaldee | US10213442 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | Feb 02, 2027 | Eirgen |
| Rayaldee | US8906410 | Oral dosage form of 25-hydroxyvitamin D | Feb 02, 2027 | Eirgen |
| Rayaldee | US9943530 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | Feb 02, 2027 | Eirgen |
| Rayaldee | US6582727 | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
Aug 22, 2020
(Expired) | Eirgen |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Calcifediol's patents.
Latest Legal Activities on Calcifediol's Patents
Given below is the list recent legal activities going on the following patents of Calcifediol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9498486 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Feb, 2024 | US9408858 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Dec, 2023 | US8207149 |
| Recordation of Patent eGrant | 31 Oct, 2023 | US11801253 |
| Patent Issue Date Used in PTA Calculation Critical | 31 Oct, 2023 | US11801253 |
| Mail Patent eGrant Notification | 31 Oct, 2023 | US11801253 |
| Recordation of Patent Grant Mailed Critical | 31 Oct, 2023 | US11801253 |
| Email Notification Critical | 31 Oct, 2023 | US11801253 |
| Patent eGrant Notification | 31 Oct, 2023 | US11801253 |
| Email Notification Critical | 12 Oct, 2023 | US11801253 |
Calcifediol's Family Patents
